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The COVID-19 pandemic prompted immense investigation of the SARS-CoV-2 virus. Rapidly, 
accurately, and easily interpreting generated data is of fundamental concern. Ontologies – structured, 
controlled, vocabularies – support interoperability, and prevent the development of data silos which 
undermine interoperability. The Open Biological and Biomedical Ontology Foundry serves to 
ensure ontologies remain interoperable through adherence by its members to core ontology design 
principles. For example, the Infectious Disease Ontology (IDO) Core includes terminological 
content common to investigations of all infectious diseases. Ontologies covering more specific 
infectious diseases, in turn, extend from IDO Core, such as the Coronavirus Infectious Disease 
Ontology (CIDO). The growing list of virus specific IDO extensions has motivated construction of 
a reference ontology covering content common to viral infectious disease investigations: the Virus 
Infectious Disease Ontology (VIDO) (https://bioportal.bioontology.org/ontologies/VIDO). 
Additionally, the present pandemic has motivated construction of a more specific extension of 
CIDO, covering terminological content specific to the pandemic: the COVID-19 Infectious Disease 
Ontology (IDO-COVID-19) (https://bioportal.bioontology.org/ontologies/IDO-COVID-19). We 
report here the development of VIDO and IDO-COVID-19. More specifically, we examine newly 
minted terms for each ontology, showcase reuse of terms from existing OBO ontologies, motivate 
choice-points for ontological decisions based on research from relevant life sciences, apply ontology 
terms to explicate viral pathogenesis, and discuss the annotating power of virus ontologies for use in 
machine learning projects.  
Introduction  
Information emerging from life science research has increasingly been recorded stored in databases. 
The sheer volume of data collected by researchers, the speed at which it is generated, range of its 
sources, quality, accuracy, and need for assessment of usefulness, results in complex, 
multidimensional datasets [30], often annotated in specific terminologies and coding systems by 
researchers in distinct disciplines. The resulting data silos [1] undermine interoperability, meta-data 
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analysis, reproducibility, pattern identification, and discovery across disciplines [12, 13]. The value of 
cross-discipline meta-data analysis is obvious, and evident in the present pandemic. Prostate cancer 
researchers [4,5] have leveraged existing research on enzymes crucial in host cell penetration by 
SARS-CoV-2 to explain differences in disease severity across sex [2,3]. Immunologists have 
combined insights from research on SARS-CoV-1 and MERS-CoV with chemical compound profile 
data, to identify drug and vaccine options for SARS-CoV-2 [6,7,8]. Pediatric researchers observing 
that children have fewer nasal epithelia susceptible to SARS-CoV-2 infection than adults, have 
suggested this difference partially explains symptom disparities between the groups [9,10]. 
Researchers [11] across the life sciences clearly recognize the need for coordinated data-driven 
efforts during the current crisis.   
 Ontologies - interoperable, logically well-defined, controlled vocabularies representing 
common entities and relations across disciplines - is a well-known solution to data silo problems. 
The present need for rapid analysis of evolving datasets representing coronavirus research motivates, 
moreover, the development of virus, coronavirus, and SARS-CoV-2 specific vocabularies. To these 
ends, we have developed the Virus Infectious Disease Ontology (VIDO; 
https://bioportal.bioontology.org/ontologies/VIDO) and the COVID-19 Infectious Disease 
Ontology (IDO-COVID-19; https://bioportal.bioontology.org/ontologies/IDO-COVID-19). Each 
is a structured vocabulary, with textual definitions for terms and relations, as well as logical axioms 
expressed in the OWL 2 Web Ontology Language (https://www.w3.org/TR/owl2-overview/), a 
World Wide Web Consortium (https://www.w3.org/) language developed for the semantic web. 
The formal representations of these ontologies support automated consistency checking, querying 
over relevant datasets, and interoperability with existing data on the semantic web. VIDO is an 
extension of the widely-used Infectious Disease Ontology Core (IDO Core; 
https://bioportal.bioontology.org/ontologies/IDO), comprised of terminological content common 
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to all investigations of infectious disease. VIDO extends to the domain of infectious diseases caused 
by viruses, and is comprised of terminological content common to investigations of viral disease, 
classification, epidemiology, replication, vaccinology, and rational drug design. VIDO provides a 
carefully curated foundation for ontologies representing specific viral infectious diseases such as 
IDO-COVID-19, an extension of VIDO to the disease COVID-19 and its causative virus SARS-
CoV-2.  
 VIDO and IDO-COVID-19 are available under the Creative Commons Attribution 4.0 
license (https://creativecommons.org/licenses/by/4.0/) and up-to-date versions of each are found 
at the National Center for Biomedical Ontology (NCBO) Bioportal [104], the Ontobee repository 
(http://www.ontobee.org/), and the Ontology Lookup Service (https://www.ebi.ac.uk/ols/index). 
Each ontology was developed in collaboration with relevant domain experts, such as immunologists, 
virologists, ontologists, and logicians, and aligns with principles outlined by the OBO Foundry [15], 
thereby supporting interoperability with existing Foundry ontologies [14]. Development of the 
ontologies is transparent, with discussions available on GitHub (https://github.com/) as part of an 
organization covering IDO Core extension ontologies (https://github.com/infectious-disease-
ontology-extensions). VIDO and IDO-COVID-19 term additions are driven by the needs of 
researchers investigating viruses, COVID-19, and nearby domains. Consequently, neither is claimed 
to be exhaustive of its respective domain, and each remains sensitive to evolving knowledge.  
Methods 
OWL, Protégé, Mace4, and Prover9 
VIDO and IDO-COVID-19 are underwritten by the OWL 2 Web Ontology Language used to 
represent ontologies in the semantic web. OWL is an expansion of the Resource Description 
Framework (RDF; https://www.w3.org/TR/rdf-primer/) and RDF Schema which represent data 
as sets of subject-predicate-object directed graphs, and which can be queried using the SPARQL 
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Protocol and RDF Query (SPARQL; https://www.w3.org/TR/sparql11-query/). OWL 
supplements these languages by allowing for description of classes, members of classes, relations 
among individuals, and annotation properties. Formally, OWL is a decidable fragment of first-order 
logic, meaning there is an algorithm which can determine the truth-value for any statement 
expressed in the language in a finite number of steps [105]. Restricting expressions to a decidable 
language allows automated consistency and satisfiability checking.  
 VIDO and IDO-COVID-19 were developed using the Protégé-OWL editor 
(https://protege.stanford.edu/) and tested against automated reasoners such as HermiT [17] and 
Pellet [18]. Additionally, logical axioms underwriting these ontologies were translated into a syntax 
readable by the Mace4 (https://www.cs.unm.edu/~mccune/prover9/) model checker, which 
allowed for manual graphical inspection of classes of models constrained by the asserted axioms. An 
automated proof-checker Prover9 (https://www.cs.unm.edu/~mccune/prover9/) bundled with 
Mace4 was used to validate expected theorems while refining axiom models.  
Alignment with OBO Foundry Ontologies 
Ontologies are widely used in bioinformatics and biomedical data standardization, supporting data 
integration, sharing, reproducibility, and automated reasoning. The Gene Ontology (GO; 
https://bioportal.bioontology.org/ontologies/GO), for example, maintains species-neutral 
annotations of gene products and functions, and – since its inception in 2000 – has inspired an 
explosion of biomedical ontologies covering domains of relevant chemicals, diagnostic tools and 
methods, human diseases, and their causes [20,21,22]. These early developments led to worries, 
however, that data silos – the very problem ontologies were designed to address – might reemerge 
[1] as researchers developed ontologies using concepts local to their discipline. By 2007, the Open 
Biomedical and Biological Ontologies (OBO) Foundry [14] was created to provide guidance for 
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ontology developers and promote alignment and interoperability while structuring data. The OBO 
Foundry design principles require ontologies: 
• Use a well-specified syntax 
• Share a common space of identifiers  
• Be openly available in the public domain for reuse  
• Be developed in a collaborative effort with ontologies covering nearby domains 
• Be developed in a modular fashion 
• Have a clearly specified scope  
• Use common unambiguously defined relations between their terms 
• Conform to a common top-level architecture  
The OBO library (http://obofoundry.org/) presently consists of over 200 ontologies, including 
some externally developed ontologies such as the NCI Thesaurus 
(https://ncithesaurus.nci.nih.gov/ncitbrowser/) and the NCBI Taxonomy 
(https://www.ncbi.nlm.nih.gov/taxonomy), and some constructed ab initio to satisfy OBO Foundry 
principles. At its core is Basic Formal Ontology (BFO; 
https://bioportal.bioontology.org/ontologies/BFO), which is an ISO/IEC approved standard 
21838-2 (https://www.iso.org/standard/74572.html; https://standards.iso.org/iso-iec/21838/-
2/ed-1/en/). BFO is a top-level ontology covering general classes such as material entity, quality, 
process, function, and role [1,23,24,25], and provides the architecture adverted in the last Foundry 
principle.  
Where BFO is domain-neutral, OBO Foundry ontologies are domain-specific, meaning they 
represent types of entities in more specific domains, using terms such as disease, cell division, surgical 
procedure, and so forth. Each domain ontology is constructed using a methodology for formulating 
definitions through a process of downward population from BFO. The resulting alignment with 
BFO, and the conformance to OBO Foundry principles, foster integration across ontologies. VIDO 
and IDO-COVID-19 were designed with alignment and conformance in mind. In the interest of 
reusability, development of each ontology followed metadata conventions exhibited by many OBO 
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Foundry ontologies [16]. These conventions require every term introduced to the ontology have a 
unique IRI, include textual definitions, definition source, designation of term editor(s), editor(s) and 
preferred term label. In the interest of coordinating development with existing OBO ontologies, 
VIDO and IDO-COVID-19 developers imported terms where possible from existing OBO library 
ontologies, and constructed logical definitions using imported terms. Development was guided, 
moreover, by best practices for definition construction [1,33]. New primitive terms were introduced 
when needed, after consultation with domain experts, relevant literature, and careful examination of 
the OBO library to avoid redundancy. VIDO and IDO-COVID-19 development was coordinated 
over near daily video conferencing and Slack (https://slack.com/) communication involving globally 
dispersed developers, punctuated by presentation of results to ontologists and domain specialists, 
where critical comments were solicited and guided subsequent refinements to the ontologies.  
‘Hub’ and ‘Spokes’ Approach 
VIDO and IDO-COVID-19 follow the ‘hub’ and ‘spoke’ methodology [31,64,106] for ontology 
development. For example, VIDO - a ‘spoke’ - is extended from the Infectious Disease Ontology 
Core (IDO Core; https://bioportal.bioontology.org/ontologies/IDO) – a ‘hub’ – which is an OBO 
ontology consisting of terms, relations, natural language definitions and associated logical axioms 
representing phenomena common across infectious diseases research [26]. IDO Core has long 
provided a base from which more specific infectious disease ontologies extend, has been updated 
[31] to keep pace with scientific and top-level architecture changes [32]. Extensions of IDO Core 
covering specific infectious diseases are created, first, by importing needed terms from IDO Core 
and other OBO Foundry ontologies, and second, by constructing the domain-specific terms where 
needed to adequately characterize entities in the relevant domain. Examples include the Brucellosis 
Infectious Disease Ontology (IDOBRU; https://bioportal.bioontology.org/ontologies/IDOBRU) 
the Influenza Infectious Disease Ontology (IDOFLU; 
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https://bioportal.bioontology.org/ontologies/FLU), and more recently the Coronavirus Infectious 
Disease Ontology (CIDO; https://bioportal.bioontology.org/ontologies/CIDO), each a member 
OBO library and semantically interoperable with other library ontologies [27,28,29,30]. Several 
extensions are illustrated in Figure 1.  
 
Figure 1: IDO Core and Sample Extensions - the Brucellosis Infectious Disease Ontology (IDOBRU), the 
Meningitis Infectious Disease Ontology (IDOMEN), the Influenza Infectious Disease Ontology (IDOFLU), the 
Coronavirus Infectious Disease Ontology (CIDO), the Malaria Infectious Disease Ontology (IDOMAL) 
 
VIDO was designed to occupy ontological space between virus-specific ontologies and IDO Core, 
the result being, for example, CIDO and IDOFLU extending directly from VIDO. Additionally, the 
COVID-19 Infectious Disease Ontology is designed to extend from CIDO, the latter covering the 
domain of coronaviruses generally, and the former covering the domain of SARS-CoV-2 and its 
associated infectious disease COVID-19.  
Results 
The Virus Infectious Disease Ontology 
Acellular Structure. While VIDO takes IDO Core as its starting point, terms from several other 
OBO Foundry ontologies were relevant to the domain of viruses, such as the Gene Ontology (GO), 
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the Ontology of General Medical Science (OGMS; 
https://bioportal.bioontology.org/ontologies/OGMS) and the Ontology of Biomedical 
Investigation (OBI; https://bioportal.bioontology.org/ontologies/OBI) [34]. Figure 2 illustrates 
high-level relationships of ontologies we discuss in what follows. Arrows represent subclass 
relationships. For example, disease is a subclass of disposition.   
 
 Figure 2: Relationships among BFO, GO, OGMS, IDO Core, and OBI 
From OGMS, VIDO imports:  
disorder =def Material entity that is a clinically abnormal part of an extended organism. 
Where a material entity part is “clinically abnormal” if it is not expected in the life plan for entities of 
the relevant type, and is causally linked to elevated risk – exceeding some threshold – of illness, 
death, or disfunction [35].  Extended organism is imported from OGMS as well:  
extended organism =def Object aggregate consisting of an organism and all material entities 
located within the organism, overlapping the organism, or occupying 
sites formed in part by the organism. 
Which relies on the OBI term:  
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organism =def Object that is an individual living system, such as animal, plant, bacteria, or 
virus, that is capable of replicating or reproducing, growth and maintenance in 
the right environment. An organism may be unicellular or made up, like 
humans, of many billions of cells divided into specialized tissues and organs. 
Here we run into the first of several ontological puzzles that emerged while developing VIDO. The 
definition of organism in OBI includes viruses. This notably stands in contrast to how the term 
“organism” is used by researchers, who often use it to refer to cellular entities [36,37]. More 
worrisome, the textual definition asserts instances of organism are cellular. Viruses, however, are 
acellular. Debates (https://github.com/OBOFoundry/COB/issues/6) among ontology developers 
over organism have resulted in deprecation of the OBI term in favor of a nearby term from the 
Common Anatomy Reference Ontology (https://bioportal.bioontology.org/ontologies/CARO): 
organism or virus or viroid. This avoids the preceding worries but reveals two more. First, introducing 
disjunctive classes suggests closure over instances, i.e. instances are all and only organisms, viruses, 
or viroids. We should, however, avoid suggesting classes – especially in biological domains – are 
settled results of scientific discoveries [1]. Second, this disjunctive class lends itself naturally to 
intractable, unnecessary debates over whether viruses are alive since it classifies viruses alongside 
paradigmatic living entities. Decades of discussion has not resolved this admittedly fascinating 
question [38,39,40,41,42,43], and it is not obvious we need an answer for the purposes of 
ontological modelling; we should avoid prompting it.  
Rather than introduce an ad hoc disjunctive class, IDO Core and VIDO developers 
collaborated to add the following disjoint sibling class of organism to IDO:  
acellular structure =def Object consisting of an arrangement of interrelated acellular parts 
forming an acellular biological unit. 
Which is imported to VIDO, as the parent class of the term virus. The term virus is, in turn, imported 
from the NCBITaxon [44] (https://bioportal.bioontology.org/ontologies/NCBITAXON), 
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alongside other taxon terms representing entities investigated by virologists, e.g. prion, viroid, and 
satellite.  
Virus. While exhaustive of the biological domain, the NCBITaxon provides minimal ontological 
structure to virus terms, following the International Committee on Taxonomy of Viruses (ICTV). 
An issue worth noting is that ICTV guidance lacks systematic classification criteria and consequently 
leaves several viruses unclassified [45,46]. Another is that when NCBITaxon is combined with 
automated importing tools such as the widely-used Ontofox (http://ontofox.hegroup.org/) [47] the 
result may be importing of an entire ICTV hierarchy - stretching from kingdom to species - resulting 
in large, unwieldy, taxonomies obscuring classes of interest. Case in point, the IDO Core extension 
IDOSCHISTO imports the entire taxonomy from kingdom to respective pathogen using OntoFox, 
making the ontology rather formidable to navigate [32].  
The NCBITaxon itself provides few textual definitions for terms. To align with OBO 
Foundry metadata conventions [16] and best practices [1,33], textual definitions and logical axioms 
are needed for virus and subclasses. Standard definitions of “virus” provide a starting point for the 
former, but caution is needed. Viruses are often described – and sometimes defined - as obligate 
pathogens [48,49], since virus replication requires host machinery for production and assembly of 
viral components. However, defining a class virus in this manner would run the risk of confusing 
what viruses are – materially speaking - with what viruses typically do. Homo sapiens are obligate 
aerobes, but this is no definition of the class. Insofar as we are defining the material entity virus, 
better to attend to genetic and structural components common to all viruses, and best to define the 
material entity in a way that captures obligate pathogenicity. With this in mind, VIDO defines:   
virus =def Acellular structure with RNA or DNA genetic material which uses host metabolic 
resources for RNA or DNA replication. 
And rather than import in accordance with the ICTV taxonomy, subclasses of virus are imported 
from NCBITaxon corresponding to a more elegant categorization of viruses: the Baltimore 
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Classification [50], which groups viruses based on features of genetic structure. There are 
accordingly seven, exhaustive, classes we import as subclasses of virus, of most relevance:  
positive-sense single-stranded RNA virus =def Virus with genetic material encoded in single-
stranded RNA that can be translated directly into 
proteins. 
Relevant because it includes the subclass:  
coronavirus =def Positive-sense single-stranded RNA virus with a helically symmetrical 
nucleocapsid, lipid bilayer viral envelope, and surface spike peplomers. 
Figure 3 illustrates the Baltimore Classification in Protégé, supplemented by a standard visual 
summary of the seven viral replication pathways underwritten by virus genetic differences.  
 
Figure 3: Baltimore Classification in Protégé Editor  
More generally, VIDO using the Baltimore Classification provides developers of more specific virus 
ontologies a succinct, navigable, ontological structure which refers to viral replication pathways, and 
so the obligate pathogenicity of viruses.   
Further VIDO subclasses of virus include those common in virology research, such as 
bacteriophage – viruses that infect bacteria – virophage – viruses that infect viruses - oncovirus – viruses 
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that cause cancer – and mycovirus – viruses that infect fungi. A subclass of virus imported from 
NCBITaxon worth discussing is the VIDO term:  
virion =def Virus that is in its assembled state consisting of genomic material (DNA or RNA) 
surrounded by coating molecules. 
Since “virion” is used in divergent ways among researchers. Some use “virion” and “virus” 
synonymously [51]. Some define “virion” so that instances only exist outside host cells [52] or 
distinguish virions outside host cells from those inside host cells, calling the former “mature 
virions.” Some claim “virion” is best understood as analogous to a sperm cell [53,54]. Ontologically 
speaking, one might model the relationship between a virus and its virion in a variety of ways, e.g. 
virion is to a virus as human infant is to human, or as human student is to human, or as human 
gamete is to human. Treating virions as gametes is uncommon among researchers, so we put that 
option aside. Between the remaining options, we adopt the first, treating virion as a type of virus, a 
stage in virus development following assembly of viral components. Adopting the alternative would 
suggest a virion is just a virus in a specific context, with a specific role.  
Incidentally, some viruses do not replicate successfully, perhaps resulting in genetically 
distinct mutants or – in extreme cases – an inactive aggregate of virion components. Virus mutations 
potentially undermine the ability of a host’s immune system to recognize that virus as a threat, as 
evidenced the difficulty in developing vaccines for certain influenza strains. Too many mutations, 
however, and a virus may lose its pathogenic and infectious dispositions, an observation used in 
development of treatments for polio and hepatitis C which exacerbate respective virus mutations 
[89,90]. VIDO provides a relevant term for tracking such differences:  
disordered virus =def Acellular structure having some arrangement of viral components (e.g. 
viral capsid, viral DNA/RNA), that is clinically abnormal 
Viruses falling in this class may even be associated with diseases much different from those of the 
clinically normal variety. Related, VIDO imports virus components from: GO such as nucleocapsid, 
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capsid, capsomere, viral envelope, the Chemical Entities of Biological Interest [55,56] ontology 
(https://bioportal.bioontology.org/ontologies/CHEBI) such as nucleic acid, ribonucleic acid, and epitope, 
and the Protein Ontology (https://bioportal.bioontology.org/ontologies/PR) such as protein and 
viral protein.   
Infectious Structure. IDO Core provides terms needed to represent pathogens, where “pathogen” 
should be understood as indexed either to a species or to stages in the developmental cycle of a 
species. With respect to the former, some viruses may engage in mutual symbiosis with one species, 
while exhibiting pathogenic behavior towards others [57,58]. With respect to the latter, mature 
plants are often susceptible to different pathogens than developing plants [59,60,61,62].  We capture 
virus pathogenic behavior in VIDO in steps. We import from IDO:  
pathogenic disposition =def Disposition borne by a material entity to establish localization in or 
produce toxins that can be transmitted to an organism or acellular 
structure, either of which may form disorder in the entity or 
immunocompetent members of the entity’s species. 
Borne by instances of the class pathogen, and:  
infectious disposition =def Pathogenic disposition borne by a pathogen to be transmitted to a 
host and then become part of an infection in that host or 
immunocompetent members of the same species as the host. 
IDO was initially designed around the class infectious agent, instances bearing an infectious disposition. 
The class infectious agent, however, is a subclass of organism, and so cannot include instances of virus. 
To address this issue, the term infectious structure was developed in consultation with IDO Core 
developers to parallel the IDO Core term infectious agent and is a logically defined subclass of acellular 
structure. The term infectious disposition bridges infectious acellular structures and infectious organisms 
since instances of each bear the same infectious disposition.  
The complexity of the definitions of pathogenic disposition and infectious disposition reflect the 
variety of pathogen examples in contemporary literature. Three preliminaries are in order before 
examining illustrative examples. First, note the term establishment of localization used in pathogenic 
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disposition is imported from GO, and is tethering or adhesion to a host, while ‘formation of disorder’ 
abbreviates two imported IDO Core terms: appearance of disorder, a process that results in the formation of a 
disorder. Second, there is an implicit temporal ordering in the textual definition of pathogenic disposition, 
which is reflected explicitly in the associated logical definition. Similarly, there is an implicit temporal 
ordering in the definition of infectious disposition between transmission to a host – represented by 
pathogen transmission process imported from the Pathogen Transmission Ontology 
(https://bioportal.bioontology.org/ontologies/PTRANS) - and becoming part of an infection – 
represented by the IDO Core process of establishing an infection. A pathogen bearing an infectious 
disposition will typically be transmitted to the host prior to establishing localization in the host and 
will typically establish infection prior to the appearance of disorder. Lastly, the term: 
infection =def Material entity part of an organism whose extended organism has some 
pathogen as part, which participates in the formation of the material entity by 
infecting the organism. 
Is imported from IDO Core as well.  
Preliminary comments in hand, the need for such complex definitions is best illustrated by 
examples. Consider, s. aureus is an opportunistic pathogen [63] in humans, becoming harmful to its 
host under changes in its environment. We count s. aureus as a pathogen, even when it does not 
realize disorder in a host, since it is nevertheless disposed to localize in a human host and generate 
disorder, if given the opportunity. This is a disposition of s. aureus – following BFO – because it is an 
‘internally-grounded’ property of the entity [64]. That is, it is part of the material basis of s. aureus to 
generate disorder in human hosts if given the chance. This is analogous to the way salt has a 
disposition to dissolve, based on its lattice structure, whether it ever realizes this disposition. Salt 
thrown in unsaturated water had a disposition to dissolve before it was immersed; just because an 
environmental change triggered manifestation does not mean salt lacked the disposition. Similarly, 
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for opportunistic pathogens, which are not pathogens because of an opportunity, but rather because 
they are disposed to localize and cause disorder in a host whether they get the opportunity or not.   
Consider now, c. botulinum, a pathogen which produces toxin spores sometimes ingested by 
humans. This bacterium counts as a pathogen for adult humans since the toxins often result in 
disorder when ingested. That said, c. botulinum may cause infection in human infants if, say honey 
colonized by c. botulinum is ingested. The sugar content of honey inhibits c. botulinum growth, but in 
the low-oxygen, low-acid intestines of human infants, spores can localize, grow, and produce toxins 
resulting in disorder. This of course counts c. botulinum as a human infant pathogen. We do not, 
however, take the further step and say c. botulinum bears an infectious disposition towards human infants, 
however, since it is not disposed to invade or be transmitted to them [121]. We leave open whether 
c. botulinum may become part of an infection in an infant. Compatibility with either characterization 
stems from the fact that being part of an infection is not itself sufficient to be counted as infectious. 
Pathogens bearing an infectious disposition must be disposed to both transmit and become part of an 
infection. Many opportunistic pathogens for example, are not infectious.  
 Immunocompetence and species membership clauses in the respective definitions of infectious 
disposition and pathogenic disposition are included to address instances where mutations in hosts may 
block realization of disorder or infection. In such cases, a pathogen may nevertheless be 
transmissible and cause disorder or infection in others. For example, HIV-1 is a pathogen that may 
localize in a host with CCR-5 mutations [65] that block the virus from attaching to host cells, and so 
block pathogenesis to AIDS. Similarly, p. falciparum may be transmitted to a host with a sickle-cell 
trait that blocks manifestation of the disease malaria [66,67]. In each case, however, the relevant 
pathogen may be transmitted to immunocompetent members of the same species as the host. Our 
definitions count these entities as pathogens, as they should be. It is worth noting, moreover, our 
claim that p. falciparum and HIV-1 count as a pathogens even if they do not result in the formation of 
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disorders for hosts with a sickle-cell trait or CCR-5 mutation, respectively, does not entail there are 
no clinical abnormalities associated with these traits or mutations. Individuals, for example, with 
CCR-5 mutations do exhibit clinical abnormalities, and so disorders. Importantly, however, this is 
not because of the HIV-1 virus. Rather, it is because of the genetic mutation. On the other hand, 
fitness pressure due to the presence of p. falciparum results in the presence of sickle-cell trait in a 
population. Consequently, the clinical abnormality associated with the sickle-cell trait is – in a broad 
sense – because of p. falciparum. Similar remarks would apply to the relationships between CCR-5 
mutations and y. pestis or v. major, if suggested selection pressure explanations involving these 
pathogens are true [108].  
Altogether, infectious dispositions are realized in localization in a host, transmission to a host, 
and generation of infection and disorder in a host or immunocompetent member of the host’s 
species, and infectious structures – such as viruses – bear this disposition. SARS-CoV-2, for example, is 
disposed – as a matter of its material composition – to be transmitted to hosts, localize, result in 
disorder and infection. Moreover, the logical definitions of infectious structure and infectious agent are 
such that, though the former is a defined subclass of acellular structure and the latter a subclass of 
organism, they are both inferred subclasses of pathogen, as they should be. 
Pathogen Host. We have mentioned “host” at several points in the preceding, and collaboration 
with the IDO Core team resulted in a ready import for this term to VIDO. Construction of the term 
was guided by recent shifts in researcher focus on host-pathogen interactions. Until recently, 
microbiologists [71,72], immunologists, virologists, and others studying pathogenesis have engaged 
in either host-centered or pathogen-centered pathogenesis research [68,69,70]. Each approach has its 
merits and has led to impressive research results. Nevertheless, emphasizing one aspect of host-
pathogen interactions at the expense of the other may leave valuable questions unanswered. 
Emphasis, for example, solely on pathogenic factors of SARS-CoV-2 will provide only a partial 
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explanation of various pathogenesis paths observed in clinical settings; focusing solely on host 
immune response is likely similarly limiting. VIDO prioritizes neither host nor pathogen in its 
representation of viruses and associated diseases, instead adopting the Damage Response 
Framework (DRF) in development of pathogen and host terms [76,77,78,79], which recognizes the 
importance of both to pathogenesis:   
(I) Pathogenesis results from interactions between host and pathogen, and attributable 
to neither alone 
(II) Host and pathogens interact primarily through damage to the host  
(III) Host damage is a function of the intensity and degree of host response and 
pathogen factors, each determined by genetic and phenotypic profiles 
Host and pathogen engage in – metaphorically – a tug of war, the result of which influences 
manifestations of signs, symptoms, and disease.  
These reflections bring us to the definitions relevant to hosts developed with IDO Core 
collaborators, then imported to VIDO:  
host role=def Role borne by an acellular structure containing a distinct material entity, or 
organism whose extended organism contains a distinct material entity, realized 
in use of that structure or organism as a site of reproduction or replication. 
pathogen host role =def Host role borne by an organism having a pathogen as part of its 
extended organism. 
symptomatic carrier role =def Pathogen host role borne by an organism whose extended 
organism contains a pathogen bearing an infectious disposition 
towards the host, and the host has manifested symptoms of the 
infectious disease caused by the pathogen. 
Where symptomatic cases of virus infection can be represented by importing from the OBO 
Foundry Symptom Ontology (https://bioportal.bioontology.org/ontologies/SYMP) terms for dry 
cough, fever, taste alteration, smell alteration, among others [80]. Given the importance of asymptomatic 
carriers in viral infection spread, moreover, special attention should be given to:  
asymptomatic carrier role =def Pathogen host role borne by an organism whose extended 
organism contains a pathogen bearing an infectious disposition 
towards the host, and the host has no symptoms of the 
infectious disease caused by the pathogen. 
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subclinical infection =def Infection that is part of an asymptomatic carrier. 
The term subclinical infection reflects standard – if not somewhat obscure – use of the terms 
“subclinical” and “asymptomatic” while nevertheless allowing for cases in which hosts with clinically 
abnormal infections exhibit no symptoms. For VIDO, this term is straightforwardly extended to 
subclinical virus infection, which is an infection caused by a virus that is part of an asymptomatic carrier.  
Note, an individual exhibiting no symptoms of infection may nevertheless exhibit signs of 
infection. Medical researchers draw a distinction between symptoms and signs, which OBO 
Foundry ontologies respect with the following imported from OGMS [35]:  
symptom =def Process experienced by the patient which can only be experienced by the 
patient, that is hypothesized to be clinically relevant. 
qualitative sign =def Abnormal observable quality of a part of a patient that is hypothesized to 
be clinically relevant. 
processual sign =def Abnormal processual entity occurring in a patient that is hypothesized to 
be clinically relevant. 
For example, an asymptomatic carrier infected with SARS-CoV-2 likely exhibits signs indicating the 
infection is clinically abnormal, such as ground-glass opacities or positive PCR test results. These 
remarks bring us full circle to the term disorder imported to VIDO, since clinical abnormality is 
associated with disorder. When that disorder stems from infection it counts as an: 
infectious disorder =def Disorder that is part of an organism whose extended organism has 
some infectious pathogen as part, which participates in the formation 
of the infection. 
And when the adverted pathogen is a virus, it falls in the VIDO class: 
virus disorder =def Infectious disorder that exists as a result of a process of formation of 
disorder initiated by a virus. 
Which can be straightforwardly extended to virus disorders involving specific viruses.  
Viral Disease. A given virus disorder will be the material basis of some associated viral disease which 
may be realized in some associated viral disease course. For example, an asymptomatic carrier of SARS-
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CoV-2 counts as both a carrier and as having the associated disease. This result aligns, moreover, 
with the CDC's case criteria adopted on April 5th, which indicates that the presence of the SARS-
CoV-2 genome in an individual is sufficient to count as a case of COVID-19, antigen presence is 
sufficient to count as likely COVID-19, and – generally speaking – asymptomatic cases should be 
counted as instances of the disease [81,82]. To represent diseases related to viruses, from IDO Core, 
VIDO imports:  
infectious disease =def Disease whose physical basis is an infectious disorder. 
infectious disease course =def Disease course that is the realization of an infectious disease. 
Where disease and disease course are themselves imported from OGMS. From these starting points, 
VIDO developers define:  
viral disease =def Infectious disease inhering in a virus disorder that is a disorder due to the 
presence of the virus. 
viral disease course =def Infectious disease course whose physical basis is a virus disorder that 
is clinically abnormal in virtue of the presence of the relevant virus. 
Once again illustrating a simple recipe for extending an ontology to a more specific domain.  
Viral Epidemiology. Changes in viral disease and infection incidence are among the targets of 
epidemiological investigation. To that end, VIDO imports from IDO Core:  
infectious disease incidence =def Quality that inheres in an organism population and is the 
number of realizations of an infectious disease for which the 
infectious disease course begins during a specified period. 
infectious disease incidence rate =def Quality that inheres in an organism population and is the 
infectious disease incidence proportion per unit time. 
infectious disease incidence proportion =def Quality that inheres in an organism population and is 
the proportion of members of the population not 
experiencing an infectious disease course at the 
beginning of a specified period of time and in whom 
the infectious disease begins during the specified 
period. 
Each of which is a quality inhering in an:  
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organism population =def Aggregate of organisms of the same species. 
These qualities underwrite the VIDO terms:  
viral disease epidemic =def Process of viral disease realizations in which there is a statistically 
significant increase in the infectious disease incidence of a 
population. 
viral disease pandemic =def Process in which multiple viral disease epidemics of the same type 
of viral disease unfold over overlapping periods of time and affect 
organism populations located in different geographic regions, 
including different countries and continents. 
Note, each is a subclass of a respective ‘infectious disease’ class imported from IDO Core. This is 
important, since “epidemic” and “pandemic” refer to diseases spread by infectious entities. Cancers 
of various sorts are widespread diseases but are not infectious, and so do not count as sustaining a 
‘cancer pandemic’ [109]. AIDS, on the other hand, is considered a pandemic, in part due to the 
transmissibility of HIV [110]. For simplicity here we focus on infectious disease, but VIDO imports 
several other important epidemiological terms, such as infection prevalence, infectivity, and infectious disease 
mortality rate. Each are qualities inhering in some material entity, though not always in some organism 
population. For example, infectivity is a quality that inheres in instances of pathogen. Additionally, 
VIDO imports terms such as:  
infection incidence =def Quality that inheres in an organism population and is the number of 
organisms in the population that become infected with a pathogen 
during a specified period. 
On which instances of infectious disease incidence depend since infectious disease realizations require 
infection. Figure 4 illustrates relationships among instances of infection, infectious incidence, viral disease 
epidemic, and viral disease pandemic over time.   
 




Figure 4: Relationships among infection incidence in a population, epidemics, and pandemic 
In words, when an infection incidence in a population increases beyond a certain threshold in a 
geographic region, this may signal an epidemic in the region. When epidemics emerge in distinct 
geographic regions, this may signal the emergence of a pandemic. Over time, a pandemic may 
involve more or fewer geographic regions, and remain a pandemic. However, once the number of 
epidemics decreases below a certain threshold, there is no longer a pandemic. Similarly, the 
distribution of infections among members of a population in a geographic region may change while 
sustaining an epidemic, but once the infection incidence falls below a certain threshold, there is no 
longer an epidemic.   
 Collaboration with IDO Core developers resulted in the introduction of subclasses of BFO’s 
process profile, essentially, a class of processes tracking changes in specific qualities in material entities 
over time [1,23]. For example, a patient’s temperature will likely fluctuate over time, as will many 
other qualities of the patient. The specific fluctuations of temperature in the patient over time is a 
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process profile, a common abstraction used in clinical diagnosis. Changes in qualities of clinical interest 
may follow several patterns, each of which can be defined as a subclass of process profile. A patient’s 
temperature may exhibit a linear increase, followed by a linear decrease. Similarly, there are process 
profile instances of irregular patterns, or as is most relevant to us here, cyclical patterns. Influenza, for 
example, exhibits complex seasonal patterns [111], which we may characterize in VIDO by defining:  
viral disease incidence profile =def Infectious disease incidence profile involving a series 
of determinate infectious disease incidence qualities 
caused by a specific virus in a population over time. 
viral disease proportion profile =def Infectious disease proportion profile that inheres in 
an organism population and is the infectious disease 
incidence caused by a specific virus per unit time. 
viral disease rate profile =def Infectious disease incidence rate profile that inheres in an 
organism population and is the infectious disease incidence 
proportion caused by a specific virus per unit time. 
Among other classes paralleling the IDO Core qualities for organism populations and pathogens 
introduced above.  
VIDO’s Relationship to CIDO 
VIDO was developed as a bridge between IDO Core and extension ontologies representing specific 
diseases and specific causative pathogens. An extension of importance during the pandemic is the 
recently developed Coronavirus Infectious Disease Ontology (CIDO; 
https://bioportal.bioontology.org/ontologies/CIDO). Developed by Oliver He and his team, 
CIDO provides semantic resources needed for representing coronavirus genome, surveillance, 
vaccine, and host data. CIDO has been used to annotate 136 known anti-coronavirus drugs [8], 
identify 110 candidate drugs [7] for COVID-19 drug repurposing [107], and provides input to 
machine learning efforts [6] in identifying potential COVID-19 vaccines. Several members of both 
and IDO and VIDO development teams are also members of the CIDO development team 
working to ensure alignment among these ontologies, and adherence to OBO Foundry principles.  
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Coronavirus Disease. CIDO can straightforwardly extend from VIDO by adopting terms such as 
the following:  
coronavirus disease =def Viral disease inhering in a coronavirus disorder. 
coronavirus disease course =def Viral disease course that is the realization of some coronavirus 
disease and has as a participant a coronavirus. 
And more generally, CIDO can be populated by starting with a given virus term from VIDO, then 
creating a subclass of that term restricted to members of the species coronavirus and associated 
causative diseases. Following representation of the Baltimore Classification in VIDO, for example, a 
subclass for positive-sense single-stranded RNA virus reflecting instances of coronavirus which can be 
imported from the NCBITaxon, and for which a definition was generated above. Features common 
to coronaviruses, can be used imported from other OBO ontologies to characterize the virus 
species, such as that the viral genome including a five-prime nucleotide cap, or the common 
glycoprotein spikes found in the viral envelope [112,113].    
Bridge to IDO-COVID-19. Following the ‘hub’ and ‘spoke’ approach to ontology development, 
CIDO in turn acts as a ‘hub’ for extension to more specific coronaviruses and associated diseases. 
Whereas CIDO includes terminological content covering existing and novel coronaviruses in 
general, and so provides resources for high-level comparison of coronavirus biological profiles, 
more specific extensions delve deeper into the transmission, genome, epidemiology, treatment, and 
so forth, for given species of coronavirus. Figure 5 illustrates various links between IDO Core, 
VIDO, CIDO, and IDO-COVID-19, among others. Several such links have been examined; we 
examine the rest as we turn to the star of the present pandemic: SARS-CoV-2.  




Figure 5: Relationships among GO, IDO Core, VIDO, CIDO, and IDO-COVID-19 
The COVID-19 Infectious Disease Ontology 
SARS-CoV-2 Pathogenesis. The starting point for IDO-COVID-19 is pathogenesis to COVID-19 
caused by SARS-CoV-2. Picking up from CIDO, IDO-COVID-19 introduces the classes:  
COVID-19 =def Coronavirus disease inhering in a SARS-CoV-2 disorder, and which is 
realized in some COVID-19 disease course. 
COVID-19 disease course =def Coronavirus disease course that is the realization of some 
COVID-19 disease and has participant SARS-CoV-2. 
Representing COVID-19 pathogenesis is of importance during the current pandemic, as researchers 
are still working to understand how SARS-CoV-2 infections cause such a wide range of signs and 
symptoms across demographics. Evidence suggests SARS-CoV-2 may evade and hijack host 
immune response as it spreads [73] resulting in an eventual overreacting immune response that may 
kill the host [74]. It is, moreover, worth noting that explaining this phenomenon invariably involves 
attention to both host and pathogen contributions to pathogenesis [75], supporting adoption of the 
Damage Response Framework as guiding ontological representation of pathogenesis to COVID-19.  
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 Representing COVID-19 pathogenesis in IDO-COVID-19 requires importing relevant 
terms from VIDO, CIDO, and relevant OBO Foundry ontologies, to define terms such as:  
SARS-CoV-2 pathogenesis =def Coronavirus pathogenesis process realization of an infectious 
structure disposition inhering in SARS-CoV-2 or a SARS-
CoV-2 population, having at least the proper process parts: 
(1) pathogen transmission, 
(2) establishment of localization in host, 
(3) process of establishing a viral infection, and  
(4) appearance of a virus disorder. 
Instances of SARS-CoV-2 pathogenesis are in turn asserted as part of some COVID-19 disease course. 
The term coronavirus pathogenesis is imported from CIDO, and is itself a subclass of the VIDO term 
viral pathogenesis, which is in turn a subclass of the term:  
pathogenesis =def Process that generates the ability of a pathogen to induce disorder in an 
organism. 
Imported from the Gene Ontology. As defined, pathogenesis is a success term, in that it 
encompasses formation of disorder in an entity. This is reflected in (1)-(4) of the SARS-CoV-2 
pathogenesis definition. This is not to say all SARS-CoV-2 infections result in successful pathogenesis. 
An individual may be infected by SARS-CoV-2, but this need not result in a relevant disorder. 
Absent the relevant disorder, there is no appropriate material basis for COVID-19. Consequently, 
this would not count as an instance of SARS-CoV-2 pathogenesis, as the process part (4) would be 
missing. Commitment to pathogenesis as a success term is analogous to the GO Consortium focus 
canonical biological processes [103]. Figure 6 illustrate how these processes are temporally related, 
and Figure 7 illustrates mereologically relationships. 




Figure 6: Sub-processes of SARS-CoV-2 Pathogenesis Temporally Ordered 
 
Figure 6: Sub-processes of SARS-CoV-2 Pathogenesis Mereologically Ordered 
Just as important as it is to represent SARS-CoV-2 pathogenesis to COVID-19, adequate 
representation of the target domain requires representation of pathogenesis to acute respiratory distress 
syndrome (ARDS), which has been one of the leading causes of death in those infected by SARS-
CoV-2 [119,120]:  
acute respiratory distress syndrome =def Progressive and life-threatening pulmonary distress in the 
absence of an underlying pulmonary condition, usually 
following major trauma or surgery. 
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From the OBO Experiment Factor Ontology (https://bioportal.bioontology.org/ontologies/EFO).  
SARS-CoV-2 pathogenesis as defined involves transmission of SARS-CoV-2 virions. From 
PTRANS (https://bioportal.bioontology.org/ontologies/PTRANS) is imported:  
pathogen transmission process =def Process during which a pathogen is transmitted directly or 
indirectly to a new host. 
From which SARS-CoV-2 specific terms can be constructed. Role terms – reflecting ‘externally-
grounded’ realizable entities in BFO, or realizable entities acquired based on circumstance such as 
the role a student takes on in university - needed to characterize transporters are imported from 
IDO Core, such as:  
pathogen transporter role =def Role borne by a material entity in or on which a pathogen is 
located, from which the pathogen may be transmitted to a new 
host. 
A respiratory droplet carrying SARS-CoV-2 expelled from an infected individual may be inhaled by 
an organism, leading to establishment of SARS-COV-2 in parts of the organism permitting the virus 
to replicate. IDO-COVID-19 imports needed terms to capture transmission from the 
Environmental Ontology (https://bioportal.bioontology.org/ontologies/ENVO):  
respiratory droplet =def Respiratory secretion composed of bounded portion of liquid which 
maintains its shape due to surface tension 
Combining with the term fomite from IDO Core, to create:  
respiratory droplet SARS-CoV-2 fomite =def Respiratory droplet fomite with SARS-CoV-2 part 
Instances of which are common targets of research in transmission studies.  
Knowledge of transmission steps supports strategies designed to break the transmission 
chain. The OBO library already includes an ontology – APOLLO-SV - which contains terms useful 
in representing various transmission control strategies 
(https://bioportal.bioontology.org/ontologies/APOLLO-SV). Given the variety of strategies 
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employed during the pandemic, IDO-COVID-19 imports liberally from this ontology. Two 
examples are:  
contact tracing =def Infectious disease control strategy that identifies and treats contacted 
organisms in a host population 
quarantine control strategy =def Infectious disease control strategy whereby asymptomatic 
carriers who have had contact with pathogens are prevented 
from having contact with other susceptible organisms 
Other APOLLO-SV classes are needed to adequately capture these strategies, in particular, classes 
populated from each of the Information Artifact Ontology 
(https://bioportal.bioontology.org/ontologies/IAO) parents imported by APOLLO-SV, action 
specification, objective specification, and plan specification, the first and second parts of the third.  
SARS-CoV-2 Replication. SARS-CoV-2 pathogenesis involves replication in a host. The term virus 
replication is defined in VIDO as a subclass of the IDO Core term replication, specifically:  
virus replication =def Replication process in which a virus containing some portion of genetic 
material inherited from a parent virus is replicated. 
And instances of viral disease course and virus pathogenesis have as respective parts virus replication. CIDO 
and IDO-COVID-19 introduce expected terms, the latter extended from the former:  
SARS-CoV-2 replication =def Coronavirus replication in which SARS-CoV-2 is replicated. 
SARS-CoV-2 replication occurs within an: 
incubation process =def Process beginning with the establishing of an infection in a host and 
ending with the onset of symptoms by the host, during which 
pathogens are multiplying in the host.  
Which has an associated incubation interval which precedes the: 
communicability interval =def One-dimensional temporal region during which a pathogen host 
bears a contagiousness disposition. 
An incubation process has proper part some:  
latency process =def Process beginning with the establishing of an infection in a host and 
ending when the host becomes contagious, during which pathogens are 
multiplying in the host. 
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Which itself has as proper part an:  
eclipse process =def Process beginning with the establishment of a virus in a host and ending 
with the first appearance of a virion following viral release, during which 
an infecting virus is uncoating to begin genome replication.  
The last being specific to viruses, so specifically a VIDO term. The remaining terms are imported to 
IDO-COVID-19 from IDO Core. Incubation is another relevant virus-specific term from VIDO: 
viral dormancy interval =def One-dimensional temporal region on which a virus is no longer 
replicating but remains within a host cell and which may be 
reactivated to begin replication again. 
Exhibited by familiar viruses such as varicella zoster and herpes simplex. 
 Careful curation of these terms is important given that evidence of confirmed cases of 
SARS-CoV-2 infection after previous apparent virus clearance have emerged [93,94,95]. There is 
presently insufficient evidence to determine whether these are novel reinfection by SARS-CoV-2 or 
reemergence of a dormant SARS-CoV-2 infection. IDO-COVID-19 provides resources to represent 
either hypothesis, the latter with a viral dormancy process in which instances of SARS-CoV-2 participate.  
IDO-COVID-19 imports the newly minted generative stage from IDO Core, defined as a 
temporal subdivision of a developmental process, as well as: 
virus generative stage =def Infectious structure generative stage that is a temporal subdivision of 
a virus developmental process. 
Subclasses of which include the various stages through which viruses may proceed during a given 
replication. Of importance here, are terms imported from GO:  
virus attachment stage =def Virus generative stage during which a virion protein binds to 
molecules on the host surface or host cell surface projection. 
virus penetration stage =def Virus generative stage during which a virion or viral nucleic acid 
breaches the barriers of a host. 
From which the following are defined in IDO-COVID-19:  
SARS-CoV-2 attachment stage =def Virus attachment stage during which SARS-CoV-2 bonds 
with a host cell.  
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SARS-CoV-2 penetration stage =def Virus penetration stage during which SARS-CoV-2 
penetrates a host cell. 
Figure 7 illustrates relationships among stages.  
 
Figure 7: SARS-CoV-2 Replication Generative Stages 
SARS-CoV-2 Susceptibility. Not all cells are susceptible to SARS-CoV-2 infection. In those cases 
of successful infection, the virus attaches to alveolar epithelial cell with a spike surface glycoprotein, 
by way of these host cell’s angiotensin-converting enzyme 2 (ACE2) receptors [85,86,87]. ACE2 
receptors appear crucial for SARS-CoV-2 attachment, suggesting the need for:  
SARS-CoV-2 adhesion susceptible cell =def Virus adhesion susceptible cell bearing a SARS-
CoV-2 adhesion disposition.  
Cells lacking ACE2 receptors seem protected from attachment by SARS-CoV-2. As mentioned in 
the introduction, pediatric researchers have suggested lower levels of ACE2 receptor bearing cells in 
the nasal epithelium of children may explain why disease severity is much lower for children than for 
adults [9,10]. The referenced adhesion disposition in the above definition is defined as:  
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SARS-CoV-2 adhesion disposition =def Virus adhesion disposition borne by a functional 
receptor that is the disposition to participate in a 
SARS-CoV-2 attachment process. 
Where the adverted functional receptor material base is imported to IDO-COVID-19 from the 
Protein Ontology (https://bioportal.bioontology.org/ontologies/PRO):  
ACE2 =def Protein complex consisting of an N-terminal peptidase M2 domain and a C-
terminal collectrin renal amino acid transporter domain, which is attached to 
surface of alveolar, enterocyte cells, arterial and venous endothelial cells, and 
cortical neurons. 
A SARS-CoV-2 attachment stage is frequently followed by a penetration stage, involving penetration 
susceptible cells. More specifically, transmembrane protease serine 2 (TMPRSS2) aids in cleaving 
host cells in anticipation of SARS-CoV-2 fusing with the cell membrane [88], then introducing viral 
genomic RNA into the cytoplasm. This similarly suggests a need to define SARS-CoV-2 penetration 
susceptible cells in terms of:  
SARS-CoV-2 penetration disposition =def Virus penetration disposition borne by a functional 
receptor complex that is the disposition to 
participate in a SARS-CoV-2 penetration process 
Where in this case the functional receptor material base is TMPRSS2, also imported to IDO-
COVID-19 from the Protein Ontology. Reflection on other stages suggest corresponding terms, 
since following penetration SARS-CoV-2 genome translation and virion assembly begins in the 
endoplasmic reticulum, forming virions then packaged into vesicles, sent to the host Golgi 
apparatus, and fused with the host cell membrane to exit the host.  
 IDO-COVID-19 terms reflecting stages of the replication cycle for SARS-CoV-2 also 
provide targets for regulation of that cycle, important to vaccine, drug, and treatment options. 
Examples of negative regulation relevant here are:  
negative regulation of SARS-CoV-2 attachment =def Negative regulation of coronavirus 
replication process that stops, prevents, or 
reduces the frequency of some SARS-CoV-
2 attachment stage. 
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negative regulation of SARS-CoV-2 penetration =def Negative regulation of coronavirus 
replication that stops, prevents, or reduces 
the frequency of some SARS-CoV-2 
penetration stage. 
Vaccine trials illustrate the importance of replication [96]. Moderna Therapeutics announced on July 
27th the third phase of its clinical trials for the vaccine mRNA-1273, which will test the vaccine in 
30,000 U.S. participants. [97,98]. The mRNA vaccine works by introducing a small segment of 
synthesized SARS-CoV-2 RNA which triggers the immune system to generate viral proteins, which 
facilitate recognition and elimination of the virus before it spreads throughout the host. On July 27th, 
Pfizer launched a combined second and third phase clinical trial examining another potential vaccine 
BNT162b2 exploring diverse populations in areas with high SARS-CoV-2 transmission rates from 
39 U.S. states, Brazil, Argentina, and Germany [99]. BNT162b2 differs from mRNA-1273 in that the 
vaccine prompts host cells to produce the entire spike protein – rather than only part of it – which 
researchers believe will provide protection in more diverse populations. The University of Oxford is 
entering a third phase of clinical trials with a viral vector vaccine ChAdOx1 nCoV-19, which 
transfers the SARS-CoV-2 spike protein the virus uses to invade cells to an attenuated adenovirus, 
which often causes the common cold, in hopes of triggering immune response to the presence of 
the spike protein [100]. In each case, vaccines regulating the spread of SARS-CoV-2 in hosts can be 
represented in part by negative regulation classes.  
Annotations. Cells infected with SARS-CoV-2 eventually trigger an immune response. The details 
are complex, as one should expect, but can be represented in IDO-COVID-19 by importing where 
possible and defining where needed. We here illustrate the extent of coverage. Consider the 
following overview of SARS-CoV-2 pathogenesis, where words in bold reflect terms included in 
IDO-COVID-19 and related ontologies:  
Cell lysis of SARS-CoV-2 causes host cells to undergo pyroptosis, releasing ATP, 
nucleic acids, ASC oligomers, and other molecules whose function is to warn nearby 
cells. When recognized by epithelial cells, endothelial, and alveolar macrophages, a 
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cascade of pro-inflammation cytokines and chemokines are released. These proteins, 
which include IL-6, IP-10, MCPI, among others [91], attract T cells, macrophages, and 
monocytes to the site of infection, promoting inflammation. A feedback loop emerges, 
whereby inflammation is promoted and promotes further inflammation. In disordered 
immune systems, immune cells accumulate in the lungs, which are damaged by 
inflammation. At such point, a “cytokine storm” [92] propagates to and damages other 
organs. In normal immune systems, inflammation attracts T cells which neutralize 
SARS-CoV-2 at the site of infection. Antibodies circulate, preventing SARS-CoV-2 
infection, and alveolar macrophages recognize SARS-CoV-2 and eliminate virions via 
phagocytosis [114].    
In more a more ontologically oriented language, we speak of the relevant part of a host’s immune 
response as being disposed to manifest a response that eliminates SARS-CoV-2 infection, while 
SARS-CoV-2 has a disposition to block manifestation of this immune system response.  
 Similarly, SARS-CoV-2 transmission can be described in a few ways, and easily represented 
in IDO-COVID-19. Consider, where again IDO-COVID-19 terms are in bold:  
SARS-CoV-2 is directly or indirectly transmitted from a reservoir through a portal of 
exit that is part of that reservoir to a portal of entry that is part of some host. SARS-
CoV-2 participates in an establishment of localization in host, then participates 
in a process of establishing an infection.  
Related, as indicated earlier asymptomatic SARS-CoV-2 infection is believed crucial for the virus 
spread [83]. “Viral shedding” occurs during the incubation period, which begins with the establishment 
of an infectious virus in a host and ends with the onset of symptoms. For SARS-CoV-2 infection 
hosts contain the highest concentration of SARS-CoV-2 virions, i.e. the viral load, during this time. 
Viral load is a common measurement of the proportion of virions to fluid (often in milliliters), and 
for SARS-CoV-2 is frequently measured from host sputum. VIDO and IDO-COVID-19 provide 
the resources for annotating virus quantification:  
viral load =def Quality inhering in a portion of fluid that is the proportion of virions to 
volume of that portion of fluid 
VIDO, moreover, imports from the Uber-Anatomy Ontology 
(https://bioportal.bioontology.org/ontologies/UBERON) the term sputum, the term information 
bearing entity from the Information Artifact Ontology 
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(https://bioportal.bioontology.org/ontologies/IAO), and is measured by, measurement information content 
entity, has integer value, uses measurement unit, and milliliter measurement unit, from the Common Core 
Ontology (https://github/com/CommonCoreOntology/CommonCoreOntologies) to represent 
research such as – quoted from the Lancet [84] with terms from IDO-COVID-19 and nearby 
ontologies in bold:  
“The viral loads in throat swabs and sputum samples peaked at around 5-6 days after 
symptom onset, ranging from around 10^4 to 10^7 copies per mL during this time.”  
Similarly, VIDO provides terms for other common virus quantification metrics, such as multiplicity of 
viral infection, the ratio of virions to susceptible cells in a target area.  
 VIDO, CIDO, and IDO-COVID-19 are presently being used to annotate approximately 400 
articles in the National Library of Medicine (https://www.nlm.nih.gov/) COVID corpus, which 
report COVID-19 clinical trial, epidemiological, and pathogenesis data. The resulting ‘gold standard’ 
annotated corpus will be used to train algorithms for use in automated annotating tasks. These 
algorithms will then be used to identify patterns in rapidly evolving datasets concerning COVID-19. 
Discussion 
VIDO and IDO-COVID-19 enable representation of various points of virus-related research. Each 
fits within a broader ontological framework, and indeed fits around an existing coronavirus ontology 
CIDO. Each complies with OBO Foundry principles, and has been reviewed by several OBO 
Foundry members, as well as relevant domain experts. Terms needed were imported where possible 
to avoid redundancy, and where needed, introduced after careful development.  
 The very scope of VIDO provides challenges, however, as does the specificity of IDO-
COVID-19. Viruses are – simply put – mysterious and complex. For this reason, since inception 
attempts have been made to foster community-driven development of VIDO and IDO-COVID-19. 
The development team for each ontology spanned disciplines in life science. Additionally, to ensure 
the computational viability of the formal representation of each ontology, specialists in logic were 
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included. Often, terms were developed then presented to domain specialists for vetting, after which 
they were – more often than not - refined, through a process of collective, reflective, equilibrium. 
This aside, there is no doubt more refinement to be done, and we are eager to continue work with 
ontology developers and domain experts in the community to get the details right.  
From the other direction, the specificity of IDO-COVID-19 requires deep knowledge of 
viral epidemiology, replication, among other areas. Given the urgency of the present pandemic, 
experts on these topics are understandably busy, and so perhaps disinclined to aid in ontological 
analysis over relevant terms. Matters are made more difficulty by the novelty of the pandemic since 
research for guidance is limited. That said, our team leveraged the expertise of those able to provide 
it, and each developer has developed competence in the growing literature on COVID-19.   
As a final note, we recognize IDO-COVID-19 is not the only ontology initiative developed 
to support curation of COVID-19 data. Others include:  
• The WHO COVID-19 Rapid Version CRF, which provides a semantic data model for the 
RAPID version (23 March 2020) of the WHO’s COVID-19 case record form [115] 
• The COVID-19 Surveillance Ontology supports COVID-19 surveillance in primary care by 
facilitating the monitoring of COVID-19 cases and related respiratory conditions using data 
from multiple brands of computerized medical record systems [116] 
• The Linked COVID-19 Data Ontology uses RDF to present COVID-19 datasets from the 
European Centre for Disease Prevention and Control, John Hopkins University and the 
Robert Koch-Institut [117].  
• The NASA Jet Propulsion Laboratory’s COVID-19 Research Knowledge Graph builds a 
knowledge graph from the COVID-19 Open Research Dataset [118]  
Each, however, is a stand-alone initiative, and so each is subject to the silo problems typically found 
in ontologies developed outside the scope of OBO Foundry principles. IDO-COVID-19 is not 
susceptible to these issues, and to that extent is superior to these alternative initiatives.  
 The successful development of these ontologies reveals more work to be done. VIDO is a 
reference ontology meant to bridge IDO and virus-specific extensions. Extensions of IDO cover 
other infectious disease-causing entities. This suggests a need for reference ontology extensions of 
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IDO covering bacteria, fungi, and parasites. The methodology illustrated here in the development of 
VIDO provides a recipe for such development. IDO developers working with domain specialists to 
straightforwardly extend terms where possible, import where needed from the OBO Foundry, and 
define new terms in consultation with experts should be standard procedure. Similarly, development 
of IDO-COVID-19 as extending from CIDO should guide needed alignments of existing pathogen-
specific ontologies extending from IDO. These efforts are not, of course, as easy as following a 
simple recipe. But the methodology presented here, and alignment with OBO promoted here, will 
relieve some of the labor involved in ontology development.  
Altogether: VIDO and IDO-COVID-19 represent substantial efforts to characterize viruses 
in general and SARS-CoV-2 in particular, in a collaborative, computationally tractable manner. 
Ontologies like these are crucial in the era of ‘Big Data’ and will provide researchers needed 
resources for gathering and coordinating increasingly important life science data [101,102].  
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